Pharma
Yatharth Hospital & Trauma Care Services Ltd
YATHARTH · NSE · INE0JO301016Wednesday, 9 Sept 20262:46 pm
Market Cap—
P/E—
P/B—
EPS—
Div Yield—
ROE10.1%
ROCE10.7%
ROE10.1%
1Y Return+53.93%
Avg. Volume0.4M
Price Chart
52-Week Range
About
Yatharth Hospital & Trauma Care Services Ltd is a Pharma company listed on NSE.
Technicals
Free account
Register freeTechnicals
Create a free account to view momentum, moving averages, and delivery signals.
Quant
Premium
UpgradeQuant metrics
Upgrade to view volatility, drawdown, factor, and risk metrics.
Key Ratios
Market Cap—
Current Price₹984.85
52W High / Low₹1,024.9 / ₹538.25
Stock P/E—
Price to Book—
EPS (TTM)—
Dividend Yield—
ROE10.1%
1Y Return+53.93%
Day Change+1.87%
Profit & Loss
| Period | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Sales | ₹1,196 Cr | ₹880 Cr | ₹671 Cr | |
| Expenses | ₹977 Cr | ₹707 Cr | ₹518 Cr | |
| Operating Profit | ₹219 Cr | ₹173 Cr | ₹153 Cr | |
| OPM % | 18.3% | 19.7% | 22.8% | |
| Other Income | ₹2 Cr | ₹0 Cr | ₹3 Cr | |
| Depreciation | ₹88 Cr | ₹57 Cr | ₹29 Cr | |
| Interest | ₹7 Cr | ₹8 Cr | ₹9 Cr | |
| Profit Before Tax | ₹224 Cr | ₹172 Cr | ₹157 Cr | |
| Tax | ₹53 Cr | ₹41 Cr | ₹42 Cr | |
| Net Profit | ₹170 Cr | ₹131 Cr | ₹114 Cr | |
| EPS (₹) | 18.2 | 14.7 | 14.5 | |
| Dividend Payout % | — | — | — |
Financial history locked
Register freeRegister free to see 1 more year.
Quarterly Results
| Quarter | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Sales | ₹393 Cr | ₹342 Cr | ₹320 Cr | ₹279 Cr | |
| Expenses | ₹329 Cr | ₹292 Cr | ₹270 Cr | ₹234 Cr | |
| Operating Profit | ₹63 Cr | ₹50 Cr | ₹50 Cr | ₹46 Cr | |
| OPM % | 16.2% | 14.6% | 15.7% | 16.3% | |
| Depreciation | — | — | — | — | |
| Interest | ₹7 Cr | ₹5 Cr | ₹1 Cr | ₹0 Cr | |
| Net Profit | ₹45 Cr | ₹45 Cr | ₹43 Cr | ₹41 Cr | |
| EPS (₹) | 4.9 | 4.9 | 4.7 | 4.3 |
Quarterly history locked
Register freeRegister free to see 1 more quarter.
Balance Sheet
| Period | FY26 | FY25 | FY24 | FY23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹96 Cr | ₹96 Cr | ₹86 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹1,684 Cr | ₹1,509 Cr | ₹788 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹264 Cr | ₹12 Cr | ₹85 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹237 Cr | ₹114 Cr | ₹60 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹2,282 Cr | ₹1,731 Cr | ₹1,019 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹1,073 Cr | ₹747 Cr | ₹414 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹78 Cr | ₹0 Cr | ₹76 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | ₹363 Cr | ₹302 Cr | ₹227 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | ₹21 Cr | ₹21 Cr | ₹8 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | ₹120 Cr | ₹205 Cr | ₹81 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹627 Cr | ₹457 Cr | ₹213 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹2,282 Cr | ₹1,731 Cr | ₹1,019 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance sheet history locked
Register freeRegister free to see 1 more year.
Cash Flow
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| FY26 | ₹205 Cr | ₹-598 Cr | ₹254 Cr | ₹-140 Cr |
| FY25 | ₹131 Cr | ₹-388 Cr | ₹509 Cr | ₹253 Cr |
| FY24 | ₹-3 Cr | ₹-226 Cr | ₹304 Cr | ₹75 Cr |
| FY23 |
Cash flow history locked
Register freeRegister free to see 1 more year.
Peer Comparison
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | — | — | +14.78% | +7.18% |
| Dr Reddys Laboratories Ltd | — | — | +8.84% | -3.74% |
| Cipla Ltd | — | — | +11.77% | -5.50% |
| Apollo Hospitals Enterprise Ltd | — | — | +22.64% | +23.01% |
| Divis Laboratories Ltd | ₹2,50,065 Cr | 83.9 | +16.5% | +46.29% |
Mutual Fund Holdings
Free account
Register freeMutual fund holdings
Create a free account to see institutional ownership snapshots.
Bulk & Block Deals
Free account
Register freeBulk & block deals
Create a free account to view recent institutional deal activity.
Analyst Estimates
Free account
Register freeAnalyst estimates
Create a free account to view analyst estimate summaries.
Latest News
2026-09-06VITG Unveils Modern Managed Services and Managed Detection & Response as Part of a Broader AI and Cybersecurity Transformation across ANZPR Newswire2026-09-04Announcement under Regulation 30 (LODR)-Newspaper PublicationBSE Filing2026-09-01Emmanuelle Guégan appointed President Marketing & Services and member of TotalEnergies’ Executive CommitteeBusiness Wire
Documents & Filings
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.